Clinical Trial Update: A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating the safety and potential effects of AVB-101 in individuals with the genetic form of frontotemporal dementia caused by G…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frontotemporal Dementia

Drugs mentioned

• AVB-101

Snippet

Sponsor: AviadoBio Ltd | Conditions: Frontotemporal Dementia, FTD | Phase 1, Phase 2 | Status: RECRUITING